An Observational Study of MabThera/Rituxan (Rituximab) in Patients With Follicular Lymphoma

Hoffmann-La Roche3 enrolled

Overview

This observational study will evaluate the safety and efficacy of MabThera/Rituxan (rituximab) in previously untreated patients with follicular lymphoma. Data will be collected for 3 years

Study Type

OBSERVATIONAL

Enrollment

Conditions

Lymphoma, Follicular

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Adult patients, \>/=18 years * Patients with previously untreated follicular lymphoma (stage III-IV) according to the approved summary of product characteristics (SPC) Exclusion Criteria: * Contraindications to MabThera/Rituxan therapy according to the approved SPC

Locations (4)

Unnamed facility

Athens, Greece

Unnamed facility

Athens, Greece

Unnamed facility

Pátrai, Greece

Unnamed facility

Thessaloniki, Greece

Outcomes

Primary Outcomes

Safety: Incidence of adverse events

Time frame: 3 years

Secondary Outcomes

Progression-free survival

Time frame: 3 years

Event-free survival

Time frame: 3 years

Overall survival

Time frame: 3 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.